SEC Form 4 · accession 0001209191-18-002067

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP & Chief Commercial Officer

Period of report

Jan 2, 2018

Accepted (ET)

Jan 4, 2018 · 5:14 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001347178

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Jan 2, 2018	M	12,500	—	A	87,500	D
Common Stock^F2,F3	Jan 2, 2018	M	7,500	—	A	110,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F2,F5,F6	—	Jan 2, 2018	M	12,500	D	—	—	Common Stock	12,500	25,000	D
Restricted Stock Unit^F2,F5,F6	—	Jan 2, 2018	M	7,500	D	—	—	Common Stock	7,500	15,000	D

F1Each Restricted Stock Unit ("RSU") was previously reported on Table II on a Form 4 filed with the Securities and Exchange Commission ("SEC") on September 8, 2015.
F2Each RSU represents a contingent right to receive a share of the Issuer's Common Stock.
F3Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II.
F4Each RSU was previously reported on Table II on a Form 4 filed with the SEC on February 17, 2016.
F5The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
F6Not Applicable.